| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
Ac-DMLD-CMK (5 μM; 6 hours pre-incubation) inhibited simvastatin-induced pyroptosis and decreased cell viability in MGC-803 human gastric cancer cells [3].
|
|---|---|
| ln Vivo |
Ac-DMLD-CMK (5 mg/kg/day; intraperitoneal injection; single injection 1 hour before cisplatin administration) can inhibit the activation of caspase 3 and GSDME, alleviate renal function deterioration in cisplatin-induced acute kidney injury in male C57BL/6 mice, reduce renal tubular epithelial damage, and reduce the secretion of inflammatory cytokines [1]. Ac-DMLD-CMK (5 mg/kg; intraperitoneal injection; single administration 3 hours before cecal ligation and perforation (CLP)) can significantly alleviate CLP-induced acute lung injury in male C57BL/6J mice by inhibiting caspase-3/GSDME-mediated pyroptosis and apoptosis, as evidenced by a decrease in lung injury score, inflammatory mediator levels, and cell death markers [2].
|
| Animal Protocol |
Animal/Disease Models:C57BL/6 (male, 6-8 weeks old, 20-25 g, cisplatin-induced) [1]
Doses: 5 mg/kg/day Route of Administration: Intraperitoneal injection; single injection 1 hour before cisplatin administration Experimental Results: Compared with mice treated with cisplatin alone, serum creatinine and blood urea nitrogen levels were reduced. Renal tubular epithelial cell death was reduced. The levels of cleaved Gsdme (Gsdme-N) and cleaved caspase 3 were reduced in mice, but had no significant effect on full-length Gsdme (Gsdme-FL). The mRNA expression of Ngal, Il6, Tnfa and Il1b in the kidneys was inhibited; the expression of Kim1 was not affected. Animal/Disease Models:C57BL/6J (male, 6-8 weeks old, sepsis model induced by cecal ligation and perforation) [2] Doses: 5 mg/kg Route of Administration: Intraperitoneal injection; single administration (3 hours before cecal ligation and perforation) Experimental Results: Compared with the cecal ligation and perforation group, the lung coefficient was reduced. Lung histopathology was improved, with reduced alveolar wall thickening, congestion, hemorrhage and inflammatory cell infiltration, and a lower lung injury score. Lung ultrastructural damage was reduced, including type II alveolar epithelial cell edema, mitochondrial structural damage and reduced lamellar body vacuolation. Compared with the cecal ligation and perforation group, the protein expression of GSDME-N and cleaved-caspase-3 in lung tissue was reduced. Compared with the CLP group, the mean fluorescence intensity of GSDME in lung tissue was reduced. Compared with the CLP group, caspase-3 activity in lung tissue was decreased. Serum lactate dehydrogenase (LDH) and interleukin-6 (IL-6) levels were decreased compared with the CLP group. The proportion of TUNEL-positive cells in lung tissue was decreased compared with the CLP group. Cleaved-PARP protein expression was decreased in lung tissue compared with the CLP group. IL-18 and IL-1β protein expression were decreased in lung tissue compared with the CLP group. Levels of pro-caspase-1, caspase-1, pro-IL-1β, and IL-1β were decreased in lung tissue compared with the CLP group. |
| References |
|
| Molecular Formula |
C22H35CLN4O9S
|
|---|---|
| Molecular Weight |
567.05
|
| CAS # |
2588354-33-8
|
| Sequence |
Ac-Asp-Met-Leu-{Asp-CMK}Ac-DML-{Asp-CMK}
|
| SequenceShortening |
Ac-DML-{Asp-CMK}
|
| Appearance |
Typically exists as solids at room temperature
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7635 mL | 8.8176 mL | 17.6351 mL | |
| 5 mM | 0.3527 mL | 1.7635 mL | 3.5270 mL | |
| 10 mM | 0.1764 mL | 0.8818 mL | 1.7635 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
